Author

Michael P. Dwyer

Observed names: M. P. DWYER, Michael Dwyer, Michael P Dwyer

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Trinity University, The University of Texas at Austin, Colorado State University

OpenAlex ID: A5111859699

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

2010 · David Parry, Timothy Guzi, et al. · Molecular Cancer Therapeutics · 565

PDF

Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts

1995 · Michael P. Doyle, Richard E. Austin, et al. · Journal of the American Chemical Society · 215

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

2010 · Kamil Paruch, Michael P. Dwyer, et al. · ACS Medicinal Chemistry Letters · 184

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

2011 · Timothy J. Guzi, Kamil Paruch, et al. · Molecular Cancer Therapeutics · 172

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

2007 · Waldemar Gonsiorek, Xuedong Fan, et al. · Journal of Pharmacology and Experimental Therapeutics · 128

Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist

2006 · Michael P. Dwyer, Younong Yu, et al. · Journal of Medicinal Chemistry · 120

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2

2010 · Marc Labroli, Kamil Paruch, et al. · Bioorganic & Medicinal Chemistry Letters · 75

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1

2010 · Michael P. Dwyer, Kamil Paruch, et al. · Bioorganic & Medicinal Chemistry Letters · 72

Structure‐guided discovery of cyclin‐dependent kinase inhibitors

2007 · Thierry O. Fischmann, Alan Hruza, et al. · Biopolymers · 68

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

2007 · Kamil Paruch, Michael P. Dwyer, et al. · Bioorganic & Medicinal Chemistry Letters · 68

Cyclopropane-Derived Peptidomimetics. Design, Synthesis, and Evaluation of Novel Enkephalin Analogues

2000 · Stephen F. Martin, Michael P. Dwyer, et al. · The Journal of Organic Chemistry · 65

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

2016 · Ling Tong, Wensheng Yu, et al. · Journal of Medicinal Chemistry · 50

PDF

Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists

2006 · J. Robert Merritt, Laura L. Rokosz, et al. · Bioorganic & Medicinal Chemistry Letters · 48

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors

2017 · Christopher J. Bungard, Peter D. Williams, et al. · ACS Medicinal Chemistry Letters · 45

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists

2007 · Jianhua Chao, Arthur G. Taveras, et al. · Bioorganic & Medicinal Chemistry Letters · 45

Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: A template-based approach

2013 · Michael P. Dwyer, Kartik Keertikar, et al. · Bioorganic & Medicinal Chemistry Letters · 42

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

2007 · Michael P. Dwyer, Kamil Paruch, et al. · Bioorganic & Medicinal Chemistry Letters · 40

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development

2016 · Anilkumar G. Nair, Qingbei Zeng, et al. · Bioorganic & Medicinal Chemistry Letters · 27

Application of AlMe3-mediated amidation reactions to solution phase peptide synthesis

1998 · Stephen F. Martin, Michael P. Dwyer, et al. · Tetrahedron Letters · 26

CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective

2014 · Michael Dwyer, Younong Yu · Current Topics in Medicinal Chemistry · 21

Iodocyclopropanes as versatile intermediates for the synthesis of substituted cyclopropanes

1998 · Stephen F. Martin, Michael P. Dwyer · Tetrahedron Letters · 21

CXCR2 modulators: a patent review (2009 – 2013)

2014 · Michael P Dwyer, Younong Yu · Expert Opinion on Therapeutic Patents · 19

Synthesis and structure–activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists

2008 · Younong Yu, Michael P. Dwyer, et al. · Bioorganic & Medicinal Chemistry Letters · 19

Structure–activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors

2016 · Ling Tong, Wensheng Yu, et al. · Bioorganic & Medicinal Chemistry Letters · 17

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors

2016 · Michael P. Dwyer, Kerry M. Keertikar, et al. · Bioorganic & Medicinal Chemistry Letters · 17

Works count: 143

Citation count: 2,380

H-index: 21

I10-index: 36